APA (7th ed.) Citation

Li, B., Cheng, S., Xiao, J., Liu, S., & Tang, L. (2025). Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma. BMJ Open, 15(4), . https://doi.org/10.1136/bmjopen-2024-090992

Chicago Style (17th ed.) Citation

Li, Bin, Shuqiao Cheng, Jian Xiao, Shao Liu, and Lanhua Tang. "Tremelimumab Plus Durvalumab Versus Sorafenib in First-line Treatment of Unresectable Hepatocellular Carcinoma." BMJ Open 15, no. 4 (2025). https://doi.org/10.1136/bmjopen-2024-090992.

MLA (9th ed.) Citation

Li, Bin, et al. "Tremelimumab Plus Durvalumab Versus Sorafenib in First-line Treatment of Unresectable Hepatocellular Carcinoma." BMJ Open, vol. 15, no. 4, 2025, https://doi.org/10.1136/bmjopen-2024-090992.